Kura Oncology's (KURA) "Buy" Rating Reaffirmed at HC Wainwright

Kura Oncology (NASDAQ:KURA - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at HC Wainwright in a research note issued to investors on Thursday, Benzinga reports. They presently have a $32.00 price target on the stock. HC Wainwright's price target would suggest a potential upside of 79.98% from the company's current price.

Other equities analysts have also recently issued reports about the company. StockNews.com cut Kura Oncology from a "hold" rating to a "sell" rating in a research note on Thursday, August 22nd. Wedbush restated an "outperform" rating and issued a $37.00 price objective on shares of Kura Oncology in a research report on Friday, August 9th. Lifesci Capital upgraded Kura Oncology to a "strong-buy" rating in a research report on Tuesday. Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a report on Monday, September 9th. Finally, JMP Securities reissued a "market outperform" rating and set a $32.00 price target on shares of Kura Oncology in a research report on Monday, August 12th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $28.83.

Kura Oncology Stock Up 4.5 %

KURA stock traded up $0.76 during trading on Thursday, reaching $17.78. 1,559,807 shares of the stock were exchanged, compared to its average volume of 902,759. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02. Kura Oncology has a twelve month low of $7.41 and a twelve month high of $24.17. The firm's 50 day moving average is $19.41 and its 200 day moving average is $20.13. The firm has a market cap of $1.35 billion, a P/E ratio of -8.19 and a beta of 0.84.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.63) by $0.04. During the same period in the prior year, the firm earned ($0.53) earnings per share. The business's revenue for the quarter was up .0% compared to the same quarter last year. As a group, research analysts forecast that Kura Oncology will post -2.45 EPS for the current year.

Institutional Trading of Kura Oncology

Institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Kura Oncology by 0.7% in the first quarter. Vanguard Group Inc. now owns 4,065,903 shares of the company's stock worth $86,726,000 after buying an additional 28,212 shares during the last quarter. Avoro Capital Advisors LLC raised its holdings in Kura Oncology by 29.2% in the 1st quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company's stock worth $82,120,000 after acquiring an additional 870,000 shares during the last quarter. Armistice Capital LLC lifted its position in Kura Oncology by 14.7% in the 2nd quarter. Armistice Capital LLC now owns 2,350,000 shares of the company's stock valued at $48,386,000 after acquiring an additional 302,000 shares in the last quarter. Artal Group S.A. boosted its stake in Kura Oncology by 8.6% during the 1st quarter. Artal Group S.A. now owns 1,919,884 shares of the company's stock valued at $40,951,000 after purchasing an additional 151,828 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Kura Oncology by 50.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 1,731,577 shares of the company's stock worth $35,653,000 after purchasing an additional 577,732 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.